| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7956187 | ALKERMES INC | Method for decreasing opioid metabolism |
Oct, 2021
(2 years ago) | |
| US8252929 | ALKERMES INC | 8-carboxamido-2,6-methano-3-benzazocines |
Oct, 2021
(2 years ago) | |
| US7262298 | ALKERMES INC | 4-hydroxybenzomorphans |
Nov, 2025
(1 year, 6 months from now) | |
| US9119848 | ALKERMES INC | Morphinan derivatives for the treatment of drug overdose |
Aug, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10716785 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US10300054 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US11351166 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US9517235 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US11793805 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US11185541 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US9126977 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Aug, 2031
(7 years from now) | |
| US11241425 | ALKERMES INC | Composition for treating mental illness |
Aug, 2031
(7 years from now) | |
| US8778960 | ALKERMES INC | Methods for treating antipsychotic-induced weight gain |
Feb, 2032
(7 years from now) | |
| US11707466 | ALKERMES INC | Immediate release multilayer tablet |
Nov, 2041
(17 years from now) | |
Lybalvi is owned by Alkermes Inc.
Lybalvi contains Olanzapine; Samidorphan L-Malate.
Lybalvi has a total of 14 drug patents out of which 2 drug patents have expired.
Expired drug patents of Lybalvi are:
- US7956187
- US8252929
Lybalvi was authorised for market use on 28 May, 2021.
Lybalvi is available in tablet;oral dosage forms.
Lybalvi can be used as method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduction of the adverse metabolic profile, method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain, method of treating schizophrenia in a patient who has previously experienced significant weight gain induced by olanzapine alone by administering a composition comprising olanzapine and samidorphan, method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, method of treating schizophrenia by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain.
Drug patent challenges can be filed against Lybalvi from 28 May, 2025.
The generics of Lybalvi are possible to be released after 12 November, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
Drugs and Companies using OLANZAPINE; SAMIDORPHAN L-MALATE ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Method of treating bipolar disorder by administering the atypical antipsychotic olanzapine and samidorphan, with reduced antipsychotic induced weight gain; Method of treating bipolar disorder by admin...
Dosage: TABLET;ORAL
LYBALVI family patents
